Literature DB >> 31247400

An overview of anti-epileptic therapy management of patients with malignant tumors of the brain undergoing radiation therapy.

Diana A R Julie1, Zartaj Ahmed2, Stephen C Karceski3, Susan C Pannullo4, Theodore H Schwartz4, Bhupesh Parashar5, A Gabriella Wernicke6.   

Abstract

As our surgical, radiation, chemotherapeutic and supportive therapies for brain malignancies improve, and overall survival is prolonged, appropriate symptom management in this patient population becomes increasingly important. This review summarizes the published literature and current practice patterns regarding prophylactic and perioperative anti-epileptic drug use. As a wide range of anti-epileptic drugs is now available to providers, evidence guiding appropriate anticonvulsant choice is reviewed. A particular focus of this article is radiation therapy for brain malignancies. Toxicities and seizure risk associated with cranial irradiation will be discussed. Epilepsy management in patients undergoing radiation for gliomas, glioblastoma multiforme, and brain metastases will be addressed. An emerging but inconsistent body of evidence, reviewed here, indicates that anti-epileptic medications may increase radiosensitivity, and therefore improve clinical outcomes, specifically in glioblastoma multiforme patients.
Copyright © 2019 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-epileptic drugs; Anticonvulsant drugs; Brain metastases; Brain tumor; External beam radiotherapy; Glioblastoma multiforme; Glioma; Radiation; Seizure; Stereotactic radiosurgery; Surgery

Year:  2019        PMID: 31247400     DOI: 10.1016/j.seizure.2019.06.019

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

Review 1.  Antiepileptic Drugs in the Management of Cerebral Metastases.

Authors:  Meredith A Monsour; Patrick D Kelly; Lola B Chambless
Journal:  Neurosurg Clin N Am       Date:  2020-10       Impact factor: 2.509

2.  Erythema Multiforme Associated With Phenytoin and Cranial RadiationTherapy (EMPACT) Syndrome Associated With Cranial Radiotherapy and Levetiracetam: A Case Report.

Authors:  Tugba Yilmaz; Berrin B Yavuz; Gul Kanyilmaz; Meryem Aktan; Selami A Temiz
Journal:  Cureus       Date:  2022-02-07

3.  Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma.

Authors:  Katharina Seystahl; Felix Boakye Oppong; Emilie Le Rhun; Caroline Hertler; Roger Stupp; Burt Nabors; Olivier Chinot; Matthias Preusser; Thierry Gorlia; Michael Weller
Journal:  Neurooncol Adv       Date:  2022-07-07

4.  Influence of Epilepsy on the Quality of Life of Patients with Brain Tumors.

Authors:  Stanisław Krajewski; Magdalena Wójcik; Marek Harat; Jacek Furtak
Journal:  Int J Environ Res Public Health       Date:  2021-06-12       Impact factor: 3.390

5.  Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study.

Authors:  Dario Di Perri; Emmanuel Jouglar; Ellen Blanc; Anne Ducassou; Aymeri Huchet; Céline Vigneron; Alexandre Escande; Sophie Chapet; Julie Leseur; Valérie Bernier; Christian Carrie; Valentine Martin; Line Claude
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.